Paper Details

  1. Home
  2. Paper Details

LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma.

Author: BoslyA, BrousseN, CoiffierB, GisselbrechtC, HerbrechtR, TillyH

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study investigated the effectiveness of an intensive chemotherapy regimen (LNH-84) in treating 737 patients with aggressive lymphoma. The study found that 75% of patients achieved complete remission. The 2-year survival rate was 67%, with a similar rate of relapse regardless of whether patients received an additional intensification treatment. While the treatment was effective, it was associated with significant side effects, including low white blood cell counts, fever, and infections. The study concludes that the LNH-84 regimen is an effective treatment for aggressive lymphoma, but further research is needed to improve treatment strategies and reduce side effects.
Paper Details　
Original Abstract of the Article :
From July 1984 to September 1987, 737 patients with aggressive malignant lymphoma (ML) were treated by an intensive regimen (LNH-84) comprising three or four courses of doxorubicin, 75 mg/m2; cyclophosphamide, 1,200 mg/m2; vindesine, 2 mg/m2 x 2; bleomycin, 10 mg x 2; and prednisolone, 60 mg/m2 x 5 ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.1989.7.8.1018

データ提供：米国国立医学図書館（NLM）

Aggressive Lymphoma: A Desert Oasis of Intensive Chemotherapy

This multicenter study delves into the effectiveness of an intensive chemotherapy regimen (LNH-84) for treating aggressive malignant lymphoma (ML). The study, conducted from 1984 to 1987, involved 737 patients with aggressive ML, and assessed the effectiveness of the LNH-84 regimen in inducing complete remission (CR), achieving overall survival, and delaying relapse. The findings revealed that the LNH-84 regimen achieved a high CR rate (75%) and demonstrated significant overall survival rates. The study also examined the impact of late intensification, a randomized component of the regimen, and found that it did not significantly alter the relapse rate.

The Desert of Lymphoma: Navigating Intensive Treatment Strategies

This research sheds light on the effectiveness of an intensive chemotherapy regimen (LNH-84) in managing aggressive malignant lymphoma. The study demonstrates the regimen's ability to achieve high CR rates and improve overall survival, offering hope for patients facing this challenging disease. The research underscores the importance of personalized treatment strategies, tailoring the intensity of therapy based on individual patient characteristics and disease stage.

The Desert of Lymphoma: Finding Hope in Intensive Treatment

This research provides valuable insights into the treatment of aggressive malignant lymphoma, highlighting the potential of an intensive chemotherapy regimen (LNH-84) in achieving significant remission rates and improving overall survival. The study encourages further exploration of intensive therapeutic approaches in this complex disease, potentially leading to more effective and personalized treatment strategies for patients navigating the challenges of lymphoma.

Dr. Camel's Conclusion

This study reveals the powerful impact of intensive chemotherapy in treating aggressive lymphoma. It's like using a desert sandstorm to blast away the cancer cells. While there are risks associated with this approach, it can be a lifeline for patients facing this challenging disease.

Date :
  1. Date Completed 1989-08-29
  2. Date Revised 2017-02-10
Further Info :

Pubmed ID

2474057

DOI: Digital Object Identifier

10.1200/JCO.1989.7.8.1018

Related Literature

Article Analysis
・Effective treatment of lymphoma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.